Skip to main content


Merck wins Fosamax preemption case at SCOTUS

By Bloomberg Law  
   May 20, 2019

Merck & Co. notched a victory today as the U.S. Supreme Court vacated an appeals court decision and said several hundred Fosamax suits are barred by federal law and shouldn’t have been reinstated. Plaintiffs alleged Merck didn’t warn quickly enough that the osteoporosis drug could cause atypical femoral fractures—thighbone breaks that happen without impact.

Full story

Get the latest on healthcare leadership in your inbox.